Ginkgo Bioworks

#2776

Rank

$4.25B

MarketCap US

US United States

Country

Summary
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

History

On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform. On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be DNA. The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche. Trading began on September 17, 2021. The investment management firm Baillie Gifford became the largest shareholder with the purchase of 167.75 million shares on 31 March 2022.On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform. On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from Bitome, an Integrated Metabolite Monitoring Platform. On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginko will enter into a new multi-year platform collaboration with Bayer. The deal includes the integration of the R&D platform assets from Joyn Bio, a joint-venture between Leaps by Bayer investments and Ginkgo Bioworks. On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.In October 2022, Bloomberg News reported that Ginkgo Bioworks partnered with Intelligence Advanced Research Projects Activity to create a software tool to help detect when biological organisms have been genetically engineered. The tool known as ENDAR could be used to provide an early warning of bioweapons and other man-made biological threats.


Mission
Our mission is to make biology easier to engineer. We are building an organism design automation platform to enable our partners to quickly develop microbial strains for use in production and start-up applications.

Vision
Our vision is to use biology as a technology platform to enable a sustainable future. We are focused on creating and delivering biobased products that can work in harmony with nature to meet the global needs of people and the planet.

Key Team

Mr. Thomas Knight Jr. (Founder)

Mr. Austin Che (Founder, Head of Strategy & Treasurer)

Mr. Bartholomew Canton (Founder, CTO & Sec.)

Karen Tepichin (Gen. Counsel & Sec.)

Marie E Fallon (Chief Accounting Officer)

Ms. Anna Marie Wagner (Sr. VP of Corp. Devel.)

Ms. Samantha Sutton (Head of People)


Recognition and Awards
Ginkgo Bioworks has won numerous awards in recognition of its work, including being named a top disruptor in clean technology by Fast Company, a top 10 company to watch in synthetic biology by CB Insights, and one of Time Magazine’s Top 25 Best Inventions of 2019.

References
Ginkgo Bioworks
Leadership team

Dr. Jason Kelly (Founder, CEO & Director)

Dr. Reshma P. Shetty (Founder, Pres, COO & Director)

Mr. Mark E. Dmytruk (Chief Financial Officer)

Products/ Services
Biopharma, Biotechnology, Chemical
Number of Employees
500 - 1000
Headquarters
Boston, Massachusetts, United States
Established
2008
Company Registration
SEC CIK number: 0001830214
Revenue
500M - 1B
Traded as
DNA
Social Media
Sun Mar 03 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium